Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L F Massuger

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 1, 1992
Specific and nonspecific immunoassays to detect HAMA after administration of indium-111-labeled OV-TL 3 F(ab')2 monoclonal antibody to patients with ovarian cancerL F Massuger, C M Thomas, M F Segers, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|November 1, 1988
Clinical applications of monoclonal antibodies against ovarian cancer-associated antigensP Kenemans, C A Yedema, J H Hilgers, et al.
Journal of Magnetic Resonance Imaging : JMRI|March 29, 2001
Post-radiotherapy contrast enhancement changes in fast dynamic MRI of cervical carcinomaE A Boss, L F Massuger, L A Pop, et al.
NMR in Biomedicine|August 29, 2000
High-resolution proton nuclear magnetic resonance spectroscopy of ovarian cyst fluidE A Boss, S H Moolenaar, L F Massuger, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
CA 125 serum levels in the early post-operative period do not reflect tumour reduction obtained by cytoreductive surgeryC A Yedema, P Kenemans, C M Thomas, et al.
Nuclear Medicine Communications|October 1, 1995
Humoral anti-OV-TL 3 response after the intravenous administration of radiolabelled Fab' or F(ab')2 fragments in ovarian cancer patientsJ G Tibben, C M Thomas, L F Massuger, et al.
Nuclear Medicine Communications|December 1, 1992
Tumour detection and localization using 99Tcm-labelled OV-TL 3 Fab' in patients suspected of ovarian cancerJ G Tibben, L F Massuger, R A Claessens, et al.
Gynecologic Oncology|April 30, 2016
Rare vulvar malignancies; incidence, treatment and survival in the NetherlandsN Pleunis, M S Schuurman, M M Van Rossum, et al.
International Journal of Radiation Applications and Instrumentation. Part B, Nuclear Medicine and Biology|January 1, 1991
Tissue distribution of 99mTc, 111In and 123I-OV-TL 3 Fab' in ovarian carcinoma bearing nude miceL F Massuger, R A Claessens, K Y Pak, et al.
Nuclear Medicine and Biology|January 1, 1994
Decreased kidney uptake of technetium-99m-labelled Fab' fragments in ovarian carcinoma bearing nude mice using a cleavable chelatorJ G Tibben, L F Massuger, O C Boerman, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 1, 1992
Specific and nonspecific immunoassays to detect HAMA after administration of indium-111-labeled OV-TL 3 F(ab')2 monoclonal antibody to patients with ovarian cancerL F Massuger, C M Thomas, M F Segers, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|November 1, 1988
Clinical applications of monoclonal antibodies against ovarian cancer-associated antigensP Kenemans, C A Yedema, J H Hilgers, et al.
Journal of Magnetic Resonance Imaging : JMRI|March 29, 2001
Post-radiotherapy contrast enhancement changes in fast dynamic MRI of cervical carcinomaE A Boss, L F Massuger, L A Pop, et al.
NMR in Biomedicine|August 29, 2000
High-resolution proton nuclear magnetic resonance spectroscopy of ovarian cyst fluidE A Boss, S H Moolenaar, L F Massuger, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
CA 125 serum levels in the early post-operative period do not reflect tumour reduction obtained by cytoreductive surgeryC A Yedema, P Kenemans, C M Thomas, et al.
Nuclear Medicine Communications|October 1, 1995
Humoral anti-OV-TL 3 response after the intravenous administration of radiolabelled Fab' or F(ab')2 fragments in ovarian cancer patientsJ G Tibben, C M Thomas, L F Massuger, et al.
Nuclear Medicine Communications|December 1, 1992
Tumour detection and localization using 99Tcm-labelled OV-TL 3 Fab' in patients suspected of ovarian cancerJ G Tibben, L F Massuger, R A Claessens, et al.
Gynecologic Oncology|April 30, 2016
Rare vulvar malignancies; incidence, treatment and survival in the NetherlandsN Pleunis, M S Schuurman, M M Van Rossum, et al.
International Journal of Radiation Applications and Instrumentation. Part B, Nuclear Medicine and Biology|January 1, 1991
Tissue distribution of 99mTc, 111In and 123I-OV-TL 3 Fab' in ovarian carcinoma bearing nude miceL F Massuger, R A Claessens, K Y Pak, et al.
Nuclear Medicine and Biology|January 1, 1994
Decreased kidney uptake of technetium-99m-labelled Fab' fragments in ovarian carcinoma bearing nude mice using a cleavable chelatorJ G Tibben, L F Massuger, O C Boerman, et al.
Pageof 6